Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-weekly dulaglutide versus placebo in type 2 diabetes (Protocol H9X-MC-GBGE[b])
2015-002095-24Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dulaglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in HbA1c from baseline to 24 weeks. Started Sep 2015; status: completed.
02
Drugs
dulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2015-002095-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002095-24.